Dicuno

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dicuno

What is Dicuno?

Dicuno is a medication used to treat pain and inflammation. It contains the active substance diclofenac, which belongs to a group of medicines known as non-steroidal anti-inflammatory drugs (NSAIDs). These medications work by reducing the production of prostaglandins, which are chemicals in the body that signal pain and cause swelling.

Therapeutic Use

Dicuno is primarily used for the short-term treatment of mild to moderate acute pain. This can include various conditions such as:

  • Muscle pain and joint pain
  • Menstrual cramps (primary dysmenorrhea)
  • Dental pain
  • Back pain

How it Works

As an NSAID, the medication provides analgesic (pain-relieving) and anti-inflammatory effects. By inhibiting the cyclooxygenase (COX) enzymes, it limits the inflammatory response at the site of injury or irritation, helping to improve mobility and comfort during recovery from acute painful episodes.

Regulatory References

  1. Diclofenac: MedlinePlus Drug Information

What side effects are possible with Dicuno?

Possible Side Effects and Safety Information

Dicuno (diclofenac potassium) is a Non-Steroidal Anti-Inflammatory Drug (NSAID) whose safety profile is well-documented in regulatory texts, detailing risks across multiple body systems.

Adverse Reaction Frequency
Common (1/100): Gastrointestinal discomfort (e.g., nausea, diarrhoea, abdominal pain), headache, dizziness, rash, pruritus.
Rare (1/10,000): Hypersensitivity reactions (including anaphylaxis), gastrointestinal haemorrhage or ulceration, hepatitis, asthma.
Very Rare (<1/10,000): Severe dermatological reactions (e.g., Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis), bone marrow depression, severe hepatic or renal failure.

Serious Safety Warnings and Limitations

Regulatory authorities classify certain risks as serious and potentially life-threatening:

  • Cardiovascular Thrombotic Events: Use of diclofenac, particularly at high doses (e.g., 150 mg daily) and during long-term treatment, is associated with an increased risk of serious arterial thrombotic events, including myocardial infarction and stroke. Dicuno is contraindicated in patients with established congestive heart failure (NYHA class II-IV), ischaemic heart disease, peripheral arterial disease, or cerebrovascular disease.
  • Gastrointestinal Risk: All NSAIDs carry a risk of gastrointestinal bleeding, ulceration, or perforation, which can be fatal. This risk is higher with increasing dose and in the elderly. The drug is contraindicated in patients with active gastrointestinal ulcer, bleeding, or perforation.
  • Population-Specific Restrictions: Dicuno is contraindicated during the last trimester of pregnancy due to the risk of cardiopulmonary toxicity and renal dysfunction in the foetus. Caution is advised in the elderly and in patients with pre-existing cardiovascular risk factors, with treatment requiring the lowest effective dose for the shortest duration.

Patients should be monitored for signs of gastrointestinal complications, serious skin reactions, and cardiovascular symptoms. Use is generally not recommended in those with severe hepatic or renal impairment.

Overdose and Emergency Response

Overdose and when to seek help

The officially documented overdose profile for diclofenac, the active component in Dicuno, details both common and severe systemic manifestations and outlines regulator-mandated emergency actions.

Overdose symptoms are often initially limited to the gastrointestinal system (epigastric pain, nausea, vomiting, or possible bleeding) and the Central Nervous System (drowsiness, headache, dizziness, or blurred vision). However, official documentation warns that in cases of large ingestions, more severe, life-threatening outcomes can occur, including seizures, coma, acute renal failure, and respiratory depression.

Immediate actions are required by regulatory authorities whenever an overdose is suspected. Patients must seek medical help right away and contact emergency services or the national Poison Help hotline, as symptoms of serious toxicity may be delayed. Management is strictly confined to symptomatic and supportive care, as no specific antidote is known for NSAID toxicity. Supportive measures may include the administration of activated charcoal and hospital monitoring of vital signs, including an ECG and renal function.

Increased severity or risk is officially documented for patients with underlying conditions such as renal or hepatic impairment.


Therapeutic Uses of Dicuno

What Dicuno Treats: Main Uses and Benefits

Dicuno (diclofenac potassium) is generally relevant when supportive symptom management is appropriate across several therapeutic domains. It is applied in clinical settings that involve acute or unstable symptom patterns where symptoms may intensify temporarily, creating noticeable interference with daily functioning.

This medication is commonly used across conditions presenting with systemic or localized discomfort, including Rheumatoid Arthritis, Osteoarthritis, Ankylosing Spondylitis, and Gouty Arthritis flares. It is commonly used to help manage symptoms related to physical discomfort in Primary Dysmenorrhea (menstrual cramps) and during Acute Migraine attacks, and pain/swelling following trauma or minor surgical procedures. It is relevant for easing symptom clusters that may become intense or disruptive, including pain, stiffness, swelling, and fever.

This offers symptomatic relief that supports the patient during difficult episodes and assists with maintaining functional stability when symptoms are more noticeable.


Quick Fact: Relief for Inflammatory Symptoms

Dicuno is commonly used to help with symptoms related to inflammatory or irritative states where short-term symptomatic assistance is needed.

Regulatory References

  1. NIH DailyMed official prescribing information

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Dicuno — Official Regulatory Information

This section outlines the eligibility and non-eligibility for Dicuno (diclofenac) strictly according to official governmental regulatory documents.


Eligibility Scope Official Regulatory Status
Populations for whom use is contraindicated (Must Not Use) Known hypersensitivity to diclofenac or other NSAIDs (e.g., aspirin-induced asthma, urticaria); Active gastrointestinal ulceration, bleeding, or perforation; Severe hepatic or renal failure; Established cardiovascular diseases (e.g., CHF NYHA II-IV, Ischemic Heart Disease); Pain after Coronary Artery Bypass Graft (CABG) surgery; Pregnancy from 30 weeks gestation (third trimester).
Age-Related Eligibility Children and adolescents under 14 years are typically not established or not recommended for systemic use. Older adults require special caution and the lowest effective dose due to increased risks.
Restricted or Conditional Use (Caution Required) Patients with mild to moderate hepatic or renal impairment; Patients with a history of GI disorders or bleeding; Patients with significant cardiovascular risk factors (e.g., uncontrolled hypertension, smoking, diabetes); Pregnancy before 30 weeks gestation (use is discouraged and must be limited).

Official Eligibility Statements: Regulatory documents prohibit Dicuno use based on the presence of severe organ failure, active GI disease, and specific cardiovascular or allergic conditions. Eligibility is contingent upon the absence of these absolute contraindications. Use in reproductive populations and those with certain risk factors requires mandated caution and monitoring.

What should I know about interactions with other medicines?

Dicuno Interactions with other Medicines and Products

This section details combinations of Dicuno (diclofenac potassium) with other medicines and products that may result in altered effects, as documented in official regulatory sources.


Documented Interaction Categories

Category Practical Constraint Noted Interacting Substances
Increased Bleeding Risk Requires caution and monitoring. Anticoagulants, Antiplatelet agents, Selective Serotonin Reuptake Inhibitors (SSRIs).
Pharmacodynamic Risk Avoided due to additive adverse effects. Other systemic Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 inhibitors.
Altered Drug Levels Requires monitoring of plasma concentration. Lithium, Digoxin, Methotrexate, Phenytoin.
Nephrotoxicity Risk Requires caution and reduced dose. Ciclosporin, Tacrolimus.
Hypertension/Renal May reduce therapeutic effect. Diuretics and antihypertensive agents (ACE inhibitors, beta-blockers).
Exposure Changes May lead to increased plasma levels. Potent CYP2C9 inhibitors (e.g., Voriconazole).

Summary of Interaction Constraints

Co-administration with other NSAIDs is officially restricted to avoid increased gastrointestinal and other adverse events. The combination with anticoagulants and antiplatelet agents necessitates careful patient monitoring due to the elevated risk of bleeding. Furthermore, regulatory labeling notes that Dicuno can raise the plasma concentrations of drugs such as Lithium and Digoxin, mandating serum level checks. Concomitant use with agents like methotrexate or CYP2C9 inhibitors may also lead to significant changes in drug exposure, requiring a cautious approach and potential dose review.

Mechanism of Action

How Dicuno Works: Mechanism of Action

Dicuno (diclofenac sodium) exerts its pharmacodynamic action by functioning as a non-competitive inhibitor of the Cyclooxygenase (COX) enzyme family, specifically targeting both the constitutive COX-1 and the inducible COX-2 isoforms. This interaction blocks the conversion of the lipid substrate arachidonic acid into prostanoids, which include PGE2 and other local signaling molecules.

The resulting mechanistic cascade involves the suppression of PGE2 synthesis at the site of tissue activation. This molecular event leads to the modification of local physiological processes, resulting in a decreased sensitization threshold of peripheral nociceptors, modification of vascular dynamics, and the modulation of the hypothalamic set point for body temperature.

The dual modulation of both COX-1 and COX-2 also yields system-level consequences on baseline physiological maintenance. COX-1 inhibition in the gastric mucosa suppresses the production of protective prostaglandins, while its inhibition in platelets modifies aggregation dynamics.

Dosage and Administration Information

How to Use Dicuno: Official Administration Guidelines

Dicuno (diclofenac) administration follows established guidelines regarding delivery and timing. These guidelines specify the approved routes, dosing schedules, and preparation requirements to ensure proper use.

Official Administration Scope

Attribute Official Guideline
Route of Administration Oral (Tablet, Capsule, Powder for solution) or Rectal (Suppository).
Dosing Schedule Varies by formulation; typically two to four times daily for immediate-release forms, or once daily for extended-release forms.
Timing in Relation to Meals Delayed-release tablets may be taken with food. Immediate-release capsules and oral powder should generally be taken on an empty stomach for optimal absorption.
Preparation Oral Powder must be mixed with 30 to 60 mL of water only and drunk immediately. Tablets require no preparation.
Special Procedural Conditions Delayed-release and extended-release tablets must be swallowed whole. Do not crush, chew, or split them.
Missed-Dose Rule If a dose is missed, take it as soon as remembered; however, if it is almost time for the next scheduled dose, skip the missed dose. Do not take a double dose.

Age-Group Rules

Safety and effectiveness are generally not established for children under 12 years of age for many standard indications. Dosing for approved pediatric use or for patients with hepatic or renal impairment requires careful consideration and adherence to specific adjustments. Clinical guidelines emphasize using the lowest effective dose for the shortest possible duration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dicuno

Evidence for Use in Mild to Moderate Pain Relief

Low-dose ibuprofen, the active ingredient in Dicuno, was studied for outcomes related to physical discomfort in clinical trials. These studies, primarily short-term Randomized Controlled Trials (RCTs) and systematic reviews, were evaluated in populations experiencing acute, mild-to-moderate pain from sources such as headaches or musculoskeletal strains. Researchers examined outcomes related to patient-reported outcomes describing perceived discomfort and the overall intensity of symptoms, using recognized measurement scales.

Studies report how symptoms evolved in the observed populations over short time intervals, often within the first few hours after a dose was observed in participants. Reports also included data on how long it took participants to report a change in symptom intensity. Comparisons were frequently made against an inactive substance (placebo) to help contextualize how patients reported their experience of their outcomes related to physical discomfort in the study settings.

Evidence for Use in Fever Reduction (Antipyresis)

Research examined changes in body temperature in studies focused on outcomes related to systemic or functional imbalance. These trials, often conducted during research examining temporary physiological imbalance associated with fever, focused on conditions associated with acute or disruptive episodes. Researchers monitored the change in body temperature and the duration for which that change was sustained. These studies were observed in both adult populations and, separately, in the pediatric population who were observed in research settings.

Durability and Duration of Study Follow-up

The available evidence for low-dose ibuprofen mainly comes from studies research exploring short-term symptom changes. This means the follow-up durations were limited, typically lasting only hours or, in some cases, up to a few days. Long-term effects are not fully established because there is limited information for long-term outcomes from extended, continuous use.

Key Evidence Gaps and Areas of Uncertainty

A major area of uncertainty is the lack of long-term outcomes data for the intermittent use of low-dose ibuprofen. Additionally, evidence is limited regarding the precise differences in response rates and symptom patterns between low-dose ibuprofen and other non-prescription pain relievers when was studied for identical, mild symptoms. Research provides context but not individual predictions, and currently available study results reflect the specific conditions under which they were conducted.

Key Studies & References

  1. Efficacy and safety of ibuprofen and acetaminophen in children and adults: a meta-analysis and qualitative review
  2. Label: IBUPROFEN tablet, film coated - DailyMed (FDA OTC Monograph/Label for uses, dosing, and warnings)

Frequently Asked Questions (FAQ)

Common questions about Dicuno (FAQ)


Q: What is the difference between Dicuno and regular over-the-counter pain relievers like ibuprofen?

Dicuno's active ingredient is diclofenac potassium, which is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID), similar to ibuprofen. Official product information notes that using the potassium salt form is associated with more rapid dissolution and absorption compared to other diclofenac formulations. This formulation characteristic is often studied for its more rapid absorption, which may contribute to a quicker onset.


Q: Is Dicuno the same as Voltaren or other diclofenac brands?

Dicuno is a specific brand name for the active drug diclofenac. While it shares the same core component as other brands, such as Voltaren, the specific salt (potassium versus sodium), tablet strength, or intended regulatory use may vary between products. It is important to adhere to the specific brand and formulation prescribed or recommended by a healthcare professional.


Q: Are there any specific vitamins or supplements that are known to interact with Dicuno?

Official drug information emphasizes the importance of informing a healthcare professional about all concurrent medications, including vitamins, supplements, and herbal remedies. Some regulatory documents specifically mention that using Dicuno with certain herbal remedies, such as St. John's Wort, could potentially increase the risk of bleeding or alter the medicine's plasma concentration.


Q: Should I avoid alcohol completely while using Dicuno?

Regulatory warnings indicate that consuming alcohol while taking Dicuno can increase the risk of serious side effects, particularly gastrointestinal issues and stomach bleeding. Regulatory warnings note that it is generally recommended to avoid or severely limit alcohol consumption while using this medication.


Q: Can women who are trying to conceive safely take Dicuno?

Official regulatory documents state that the use of diclofenac may impair female fertility (the ability to conceive). Due to the potential to impair female fertility, the use of diclofenac is generally not recommended for women who are trying to conceive.


Q: What is the significance of Dicuno containing diclofenac potassium instead of diclofenac sodium?

Dicuno utilizes the potassium salt of diclofenac. According to official pharmacological properties, this specific salt is formulated for rapid dissolution and absorption. This formulation is associated with faster dissolution and absorption, which may support a quicker onset of effect.


Q: Are there different strengths of Dicuno tablets, and what is the maximum daily amount?

Diclofenac products are available in a variety of strengths, such as 25 mg or 50 mg tablets, depending on the specific product. Official regulatory guidance specifies that the adult maximum recommended daily dose is typically 150 mg, or sometimes 200 mg, depending on the formulation. Regulatory labeling consistently emphasizes using the lowest effective dose for the shortest possible duration to minimize risks.


Q: Is it normal to feel a bit tired or drowsy after taking Dicuno?

Official adverse reaction reports list effects related to the nervous system, including feeling tired, drowsy (somnolence), or generally fatigued. If these effects are experienced, caution is warranted when performing activities that require full mental alertness.


Q: What kind of research or clinical evidence supports the use of Dicuno for acute pain?

Clinical studies and official information confirm the effectiveness of diclofenac for managing acute, mild-to-moderate pain from various sources, such as headaches or muscle and joint discomfort. This effectiveness is based on its established action as an anti-inflammatory and pain-relieving agent.


Q: Is it possible for Dicuno to cause fluid retention or swelling?

Yes, regulatory warnings note that fluid retention and edema (swelling) have been reported with the use of NSAIDs like diclofenac. Caution is particularly advised for patients with pre-existing conditions like heart failure or high blood pressure.


Q: What kind of joint pain is Dicuno typically used to treat?

Diclofenac is officially indicated for the management of signs and symptoms related to inflammatory joint conditions, specifically types of arthritis, such as rheumatoid arthritis and osteoarthritis. It is also used more generally for acute musculoskeletal pain.


Q: Can Dicuno be used for fever reduction?

Yes, official regulatory documents characterize the active ingredient in Dicuno, diclofenac, as possessing antipyretic (fever-reducing) properties, in addition to its anti-inflammatory and pain-relieving effects. Its use for fever reduction is part of its recognized therapeutic profile.


Q: Does Dicuno come in any other forms besides a film-coated tablet?

While Dicuno is often known as a film-coated tablet, the active ingredient diclofenac is also available in other oral forms, including capsules and oral powder for solution. Furthermore, it is available as rectal suppositories for other routes of administration.


Q: Why do some people experience ringing in their ears (tinnitus) when taking NSAIDs like Dicuno?

Tinnitus, or ringing in the ears, is listed in official adverse reaction documents as a possible undesirable effect reported in some patients taking diclofenac. This symptom is generally associated with the use of medications in the Non-Steroidal Anti-Inflammatory Drug (NSAID) class.


Q: Does Dicuno carry a risk of hypersensitivity to sunlight or photosensitivity?

Official adverse reaction reports indicate that photosensitivity reactions (hypersensitivity to sunlight) have been reported as a possible skin reaction with diclofenac. Patients are generally advised to take precautions when exposed to strong sunlight or sunbeds.


Q: What should I do if I notice unusual bruising while taking Dicuno?

Diclofenac can affect platelet aggregation, which plays a role in blood clotting, leading to an increased risk of bleeding. Because of the potential to affect blood clotting, official information advises that any signs of bleeding, such as unusual bruising, should be brought to the attention of a healthcare professional promptly.


Q: Does Dicuno affect blood clotting in the same way as aspirin?

Diclofenac is known to reversibly inhibit platelet aggregation and increase the risk of bleeding. Official labeling specifically warns that taking Dicuno concurrently with antiplatelet agents, such as aspirin, can significantly increase the risk of serious gastrointestinal side effects.


Q: Are there any age restrictions for taking Dicuno, specifically for adolescents?

Regulatory guidance specifies that systemic use of diclofenac is generally not established or recommended for children and adolescents under 14 years of age for most standard uses. For those 14 and older, dosing must strictly adhere to the specific regulatory adjustments approved for that age group.


Q: Is there a link between Dicuno use and changes in vision or eye issues?

Yes, official regulatory documents list changes in vision, such as blurred vision, as a possible adverse reaction from using diclofenac. If changes in vision are experienced, this is a symptom that regulatory documents suggest should be reported.


Q: Why is it important to take the lowest effective dose of Dicuno for the shortest time?

Official regulatory guidance strongly emphasizes using the lowest effective dose for the shortest possible duration of treatment. This instruction is critical for minimizing the potential risk of serious side effects, including cardiovascular thrombotic events and gastrointestinal complications.


Q: What are the signs that Dicuno might be affecting my kidneys?

While specific patient-observable signs are not typically listed, official warnings note the risk of renal failure and advise caution, especially in at-risk patients. As fluid retention and edema are known risks, monitoring for unexplained swelling is consistent with the general safety profile.


Q: Can Dicuno cause changes in mood or psychiatric side effects?

Diclofenac has been associated with central nervous system effects, and official adverse reaction reports list changes in mood, including anxiety and depression, as well as other psychiatric side effects.


Q: If I am taking Dicuno for chronic pain, what should I monitor for?

For prolonged or chronic treatment, regulatory documents recommend that physicians regularly monitor a patient's hepatic function (liver), renal function (kidneys), and blood counts. Patients should remain vigilant for any signs of cardiovascular or gastrointestinal complications, as risk increases with duration of use.

How should Dicuno be stored and disposed of?

Dicuno (diclofenac potassium) must be stored and disposed of according to official regulatory requirements to ensure stability and environmental protection.

Storage Conditions and Stability

The film-coated tablets must be stored below 25°C to maintain the product's quality and its labeled 5-year shelf-life. As a mandatory safety constraint, the medicine must be kept out of the sight and reach of children.


Disposal Requirements

Disposing of unused or expired Dicuno must be done in accordance with established local procedures. Regulatory instructions state the medicine must not be thrown away via wastewater or household waste. Patients should ask a pharmacist for guidance on how to properly discard the unused product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dicuno found in:

A-Z Index: